The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Greater prevalence of seropositivity for anti-cyclic citrullinated peptide antibody in unaffected first-degree relatives in multicase rheumatoid arthritis-affected families

  • Kim, Seong-Kyu (Department of Internal Medicine, Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine) ;
  • Bae, Jisuk (Department of Preventive Medicine, Catholic University of Daegu School of Medicine) ;
  • Lee, Hwajeong (Department of Internal Medicine, Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine) ;
  • Kim, Ji Hun (Department of Internal Medicine, Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine) ;
  • Park, Sung-Hoon (Department of Internal Medicine, Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine) ;
  • Choe, Jung-Yoon (Department of Internal Medicine, Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine)
  • Published : 2013.01.01
⟨ Previous Next ⟩

Abstract

Background/Aims: This study determined the prevalence and determinants of seropositivity for rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibody, and anti-mutated citrullinated vimentin (anti-MCV) antibody in unaffected first-degree relatives (FDRs) of rheumatoid arthritis (RA) patients. Methods: A total of 337 subjects (135 with RA and 202 FDRs) were enrolled in this case-control study. Serum RF, anti-CCP antibody, and anti-MCV antibody were assayed. Subjects in multicase families (${\geq}$ 2 affected FDRs within the same family) were identified. Multivariate logistic regression analysis was used to identify risk factors associated with RA-related autoantibodies. Results: Seropositivity for RF, anti-CCP antibody, or anti-MCV antibody was detected in 14.4%, 5.0%, or 13.4% of unaffected FDRs, respectively. Anti-CCP antibody seropositivity was more prevalent in FDRs in multicase families (17.8%) than in those not in multicase families (1.3%, p < 0.0001). Significant correlations between RA-associated autoantibodies were detected in the FDR group (between RF and anti-CCP antibody: r = 0.366, p < 0.0001; between RF and anti-MCV antibody: r = 0.343, p < 0.0001; and between anti-CCP antibody and anti-MCV antibody: r = 0.849, p < 0.0001). After adjustment for age and sex, anti-CCP antibody seropositivity in FDRs was significantly associated with being in a multicase family (odds ratio, 49.8; 95% confidence interval, 5.6 to 441.6). Conclusions: The association between anti-CCP antibody seropositivity in unaffected FDRs and being in a multicase family suggests that genetic and/or environmental factors may increase the risk for RA development in unaffected FDRs.

Keywords

References

  1. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010;233:233-255. https://doi.org/10.1111/j.0105-2896.2009.00859.x
  2. Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annu Rev Pathol 2009;4:417-434. https://doi.org/10.1146/annurev.pathol.4.110807.092254
  3. Lee HS, Lee AT, Criswell LA, et al. Several regions in the major histocompatibility complex confer risk for anti- CCP-antibody positive rheumatoid arthritis, independent of the $DRB_1$ locus. Mol Med 2008;14:293-300. https://doi.org/10.1007/s00894-008-0270-7
  4. Remmers EF, Plenge RM, Lee AT, et al. $STAT_4$ and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007;357:977-986. https://doi.org/10.1056/NEJMoa073003
  5. Thomson W, Barton A, Ke X, et al. Rheumatoid arthritis association at 6q23. Nat Genet 2007;39:1431-1433. https://doi.org/10.1038/ng.2007.32
  6. Baka Z, Buzas E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther 2009;11:238. https://doi.org/10.1186/ar2751
  7. Mikuls TR, Cerhan JR, Criswell LA, et al. Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2002;46:83-91. https://doi.org/10.1002/1529-0131(200201)46:1<83::AID-ART10042>3.0.CO;2-D
  8. Silman AJ, Hennessy E, Ollier B. Incidence of rheumatoid arthritis in a genetically predisposed population. Br J Rheumatol 1992;31:365-368. https://doi.org/10.1093/rheumatology/31.6.365
  9. Silman AJ, MacGregor AJ, Thomson W, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 1993;32:903-907. https://doi.org/10.1093/rheumatology/32.10.903
  10. MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-37. https://doi.org/10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B
  11. Kolfenbach JR, Deane KD, Derber LA, et al. A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using f irstdegree relatives of probands with RA. Arthritis Rheum 2009;61:1735-1742. https://doi.org/10.1002/art.24833
  12. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-2749. https://doi.org/10.1002/art.11223
  13. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specif ic autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-386. https://doi.org/10.1002/art.20018
  14. Jorgensen KT, Wiik A, Pedersen M, et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2008;67:860-866. https://doi.org/10.1136/ard.2007.073825
  15. Silman AJ, Ollier B, Mageed RA. Rheumatoid factor detection in the unaffected first degree relatives in families with multicase rheumatoid arthritis. J Rheumatol 1991;18:512-515.
  16. Hazelton RA, Cross SM, Robert G, Strachan N. A family study of the prevalence of antibodies to the rheumatoid arthritis associated nuclear antigen (RANA). Br J Rheumatol 1986;25:349-352. https://doi.org/10.1093/rheumatology/25.4.349
  17. Arlestig L, Mullazehi M, Kokkonen H, Rocklov J, Ronnelid J, Dahlqvist SR. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden. Ann Rheum Dis 2012;71:825-829. https://doi.org/10.1136/annrheumdis-2011-200668
  18. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-243. https://doi.org/10.1186/ar93
  19. Raza K, Mathsson L, Buckley CD, Filer A, Ronnelid J. Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis. Ann Rheum Dis 2010;69:627-628. https://doi.org/10.1136/ard.2009.118448
  20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324. https://doi.org/10.1002/art.1780310302
  21. Choi SW, Lim MK, Shin DH, Park JJ, Shim SC. Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis. J Korean Med Sci 2005;20:473-478. https://doi.org/10.3346/jkms.2005.20.3.473
  22. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004;4:239-262. https://doi.org/10.1016/j.cair.2003.11.001
  23. Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994;21:1027-1033.
  24. Tilleman K, Van Steendam K, Cantaert T, De Keyser F, Elewaut D, Deforce D. Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inf lammatory arthritides. Rheumatology (Oxford) 2008;47:597-604. https://doi.org/10.1093/rheumatology/ken077
  25. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-2511. https://doi.org/10.1002/art.22817
  26. Svard A, Kastbom A, Soderlin MK, Reckner-Olsson A, Skogh T. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis. J Rheumatol 2011;38:1265-1272. https://doi.org/10.3899/jrheum.101086
  27. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006;8:R119. https://doi.org/10.1186/ar2008
  28. Nicaise Roland P, Grootenboer Mignot S, Bruns A, et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther 2008;10:R142. https://doi.org/10.1186/ar2570
  29. Song JS, Park GB, Park AJ. Comparison of anti-mutated citrullinated vimentin with anti-cyclic citrullinated peptide and rheumatoid factors for the diagnostic value of rheumatoid arthritis. J Korean Rheum Assoc 2007;14:235-241. https://doi.org/10.4078/jkra.2007.14.3.235
  30. Poulsom H, Charles PJ. Antibodies to citrullinated vimentin are a specif ic and sensitive marker for the diagnosis of rheumatoid arthritis. Clin Rev Allergy Immunol 2008;34:4-10. https://doi.org/10.1007/s12016-007-8016-3

Cited by

  1. Anti-CCP Antibodies Are Not Associated with Familial Mediterranean Fever in Childhood vol.2013, pp.None, 2013, https://doi.org/10.1155/2013/498581
  2. Anti-citrullinated protein antibodies in rheumatoid arthritis: a bridge between genetic predisposition and autoimmunity vol.28, pp.1, 2013, https://doi.org/10.3904/kjim.2013.28.1.25
  3. Preclinical Rheumatoid Arthritis (Autoantibodies): An Updated Review vol.16, pp.5, 2014, https://doi.org/10.1007/s11926-014-0419-6
  4. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE vol.10, pp.4, 2013, https://doi.org/10.1038/nrrheum.2014.6
  5. Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis vol.46, pp.3, 2013, https://doi.org/10.1309/lmzytso5rhihv93t
  6. Autoantibodies in Prediction of the Development of Rheumatoid Arthritis Among Healthy Relatives of Patients With the Disease vol.67, pp.11, 2015, https://doi.org/10.1002/art.39297
  7. Association of complement factor B allotypes and serum biomarkers in？rheumatoid arthritis patients and their relatives vol.42, pp.6, 2013, https://doi.org/10.1111/iji.12232
  8. Análise de quatro marcadores sorológicos na artrite reumatoide: associação com manifestações extra‐articulares no paciente e artralgia em familiares vol.57, pp.4, 2017, https://doi.org/10.1016/j.rbr.2015.11.002
  9. Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria? vol.57, pp.11, 2013, https://doi.org/10.1515/cclm-2019-0167
  10. A new tool for early diagnosis of rheumatoid arthritis using combined biomarkers; synovial MAGE-1 mRNA and serum anti-CCP and RF vol.36, pp.None, 2013, https://doi.org/10.11604/pamj.2020.36.270.21827
  11. Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift vol.73, pp.2, 2013, https://doi.org/10.1002/art.41417